Type 2 Diabetes Mellitus Clinical Trial
Official title:
Cadence and Intensity in Adults With Type 2 Diabetes
The purpose of this study is to measure and link cadence (number of steps taken in a minute) to intensity of physical activity (e.g., low-intensity, moderate intensity, vigorous-intensity) in adults (40- 65 years-old) with type 2 diabetes.
There will be up to two lab visits for participants, all of which will be completed in the
Physical Activity and Health Lab at University of Massachusetts Amherst (consent, physical
examination and entire research protocol, 2.5-3.5 hrs for all participants).
The first visit will consist of an orientation session. This orientation will begin with
screening questions to determine eligibility and obtaining informed consent (45 min),
followed by a physical exam and resting ECG for all participants (30 min):
Screening Questions: Participants will self-report their diagnosis of type 2 diabetes and
year of diagnosis. Medication used for controlling diabetes will be determined by
participants bringing their medication bottle or a photo of its label. Participants will
answer additional questions (documentation attached) in an interview-style format with
research staff to determine eligibility (15 min). These questions will be derived from the
American Heart Association's (AHA) risk stratification found in the 2013 edition of the
American College of Sports Medicine's (ACSM's) Resource for The Health Fitness Specialist.
According to this screening, all participants with type 2 diabetes are considered high risk
but the additional cardiac, pulmonary, and metabolic disease-related questions will be used
for descriptive purposes. Given the low impact of this protocol, the volunteer's personal
physician does not need to provide clearance. The PI, who is a physician, will be available
to review individual circumstances prior to testing.
Informed Consent: Research staff will present an orientation slideshow to participants
regarding the study purpose, study procedures, and rights as a participant (slideshow
attached). Participants will then review and sign informed consent documents. (30 min)
Physical Exam: A physical exam will be conducted by study staff under the guidance of the
medical director (Stuart Chipkin, MD) to assess for medical conditions that may interfere
with the exercise protocol and ensure participant safety. In addition, the medical director
will conduct tests for diabetic neuropathy with the neuropathy symptom and change (NSC)
score, neuropathy impairment score (NIS). The NSC consists of a series of questions about
neuropathy-related pain and numbness, maneuvers that relieve symptoms, and arousal from
sleep. The NIS is a battery of tests that assess the ankle reflex as well as vibration,
pin-prick, and temperature sensation in the great toes. (15 min)
Electrocardiogram (ECG). A resting 12-lead electrocardiogram will be performed and reviewed
by the medical director prior to the exercise protocol (15 min).
Metabolic testing will then occur during the same session or a second study visit. All
testing will be overseen by trained study staff with an MS or PhD in Exercise
Science/Physiology or BS in Kinesiology as well as the medical director. These accommodations
meet the ACSM and AHA criteria for exercise protocols. Because responses to exercise are
affected by 4 hr pre-exercise food intake participants will have fasted for 4 hrs prior to
testing. The metabolic testing session will be comprised of anthropometric and demographic
information collection, instrument attachment, blood glucose measurement, and treadmill
walking:
Anthropometrics and demographic information collection: Measures will be taken of height,
seating height, body mass, body fat percentage, BMI, and waist circumference. Questions will
be asked to ascertain date of birth, gender, and race/ethnicity.
Instrument attachment: Non-invasive pedometers and accelerometers will be worn by
participants to measure/monitor movement during treadmill testing. The purpose of attaching
these devices is to test the criterion-validity of step-counting wearable devices during
treadmill walking in adults with T2DM, and compare the results to those observed with healthy
adults. This is a secondary aim of the study. Participants will also be fitted with a mobile
indirect calorimeter (facemask and back harness) and chest strap heart-rate monitor for
measuring oxygen consumption and heart-rate.
Blood glucose measurements: The medical investigator will check fingerstick glucose values
using a standard FDA-approved glucose meter before and 30 minutes after completion of
treadmill testing. Following guidelines from the American Diabetes Association (Colberg SR et
al; Diabetes Care 2016; 39:2065-2079. DOI: 10.2337/dc16-1728), any subject with a pre-test
blood glucose < 70 mg/dl will be given 15-20 grams of carbohydrate. For glucose values
between 70-150 mg/dl, study staff will administer 0.5 grams of carbohydrate per kg body mass.
In addition, the medical investigator will test glucose values at any point during the
protocol that a participant reports symptoms of hypoglycemia (low blood sugar) such as
feeling sweaty, shaky, or weak. Subjects will be given a light snack after the testing
session and informed about the potential for low blood sugars following exercise. The light
snack will consist of 15-20g of simple carbohydrates or glucose.
Treadmill walking: Throughout the treadmill walking protocol, ambulatory monitoring of ECG
and blood pressure will be conducted for ensuring participant safety Participants will
complete a series of 5-min bouts of treadmill walking. The first bout will be performed at
0.5 mph, with concurrent bouts increasing in 0.5 mph increments, and the test will be
terminated upon participant or researcher volition or completion of the first bout when the
participant 1) naturally selects to run instead of walk, 2) achieved 75% of their predicted
maximum heart rate, or 3) reported a Borg Rate of Perceived Exertion Scale (see attachment
document ) > 13, or 4) reaches a speed of 6.0 mph. Each bout will be separated by 2-5min of
standing rest on the stopped treadmill. Participants will not be seated during the resting
period, as this is a submaximal protocol and fatigue preventing its continuation and
requiring seated rest would be an indication to end the test.
During treadmill testing, cadence (steps/min) will be assessed by the number of
directly-observed steps divided by bout duration. Redundant video recording of the
participant's feet will be conducted during the entirety of treadmill testing as a back-up
method to confirm step counts. Indirect calorimetry will concurrently be used to measure
oxygen uptake.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |